Multiple sclerosis (MS) treatment options have improved significantly over the past decades, but the consequences of MS can still be devastating and the needs for monitoring treatment surveillance are
Development of effective treatments requires understanding of disease mechanisms. For diseases of the central nervous system (CNS), such as multiple sclerosis (MS), human pathology studies and animal
EBV viral load (copies per μg DNA) was grouped into 3 categories: Low: 100 to 999; moderate: 1000 to 1999, and high: ≥2000/μg DNA. Of the 40 cases with measurable viral load, 3 cases were from non-MS